At The Medical Eye Clinic, we can accurately calculate the exact power of intraocular lens your eye requires to focus light correctly, often providing fantastic distance vision without glasses. It is normal that with standard intraocular lenses reading glasses may still need to be needed. However, with improved technology we can now supply multi focal lenses by ZEISS, that can also help combat these near vision difficulties as well. We can also supply a specialist “Toric” lens which helps correct the vision of those patients who have astigmatism in their prescription.
Dr. Leder has practiced Ophthalmology for over 10 years, specializing in diseases of the retina, vitreous, and ocular inflammation. He has been involved in many clinical trials and authored dozens of publications on retinal diseases, and surgery. He has served as Editor of the Clinical Reference Systems and as a consultant for the Food and Drug Administration Division of Ophthalmic Devices, the division which clears ophthalmic medical devices for clinical use in the United States.
Certified by the American Board of Ophthalmology and a fellow of the American Academy of Ophthalmology, Dr. Leder is a graduate of Yale University and the University of Connecticut School of Medicine. He completed his internship in Internal Medicine at Ochsner Clinic Foundation and his residency in Ophthalmology at the Louisiana State University Eye Center in New Orleans. He was on call as the senior ophthalmologist in New Orleans during Hurricane Katrina, caring for patients and helping to evacuate Charity Hospital. He went on to received Advanced Subspecialty Fellowship Training in Medical Diseases of the Retina at the Duke University Eye Center. He also completed fellowships in Ocular Immunology and Uveitis, as well as Diseases and Surgery of the Retina and Vitreous at the Wilmer Eye Institute, of the Johns Hopkins University. He had the privilege to be chosen for the very prestigious position of Assistant Chief of Service (Chief Resident) at Wilmer during which time he served as the Assistant Director of the Maryland Ocular Trauma Center, and Director of the General Eye Service at Wilmer. He went on to be an Assistant Professor at Johns Hopkins University and the Albert Einstein School of Medicine.
The FDA's approval of Ozurdex was based on results from 2 randomized, double-masked, multi-center clinical studies (n = 853). The studies demonstrated a statistically significant improvement in 3 or more lines of VA in approximately 20 to 30 % of treated patients within 60 days post-implantation compared to sham. The duration of improvement continued for approximately 30 to 90 days and was effective in both CRVO and BRVO. The most significant adverse effect was an increase in intra-ocular pressure that occurred in 106 patients (25 %), which peaked at 60 days and returned to baseline levels by day 180. Three patients ( %) required laser or surgical procedures as a result. Conjunctival hemorrhage occurred in 85 patients (20 %). Ozurdex is the first FDA-approved therapy for ME related to retinal vein occlusion. The proposed benefit of a sustained-release intra-vitreal corticosteroid insert such as Ozurdex is the potential for fewer injections. Intra-vitreal injections have been associated with endophthalmitis, eye inflammation, increased intra-ocular pressure, and retinal detachments.